IL6 and metabolic syndrome: These effects drive endothelial dysfunction, insulin resistance, dyslipidemia, activation of the renin–angiotensin–aldosterone system (RAAS), and a shift toward enhanced systemic inflammation, marked by elevated levels of C-reactive protein, interleukin-6, and tumor necrosis factor-alpha.